Literature DB >> 19955273

Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneri.

Changyun Ye1, Ruiting Lan, Shengli Xia, Jin Zhang, Qiangzheng Sun, Shaomin Zhang, Huaiqi Jing, Lei Wang, Zhenjun Li, Zhemin Zhou, Ailan Zhao, Zhigang Cui, Jingjing Cao, Dong Jin, Lili Huang, Yiting Wang, Xia Luo, Xuemei Bai, Yan Wang, Ping Wang, Qiang Xu, Jianguo Xu.   

Abstract

Shigella spp. are the causative agent of shigellosis with Shigella flexneri serotype 2a being the most prevalent in developing countries. Epidemiological surveillance in China found that a new serotype of S. flexneri appeared in 2001 and replaced serotype 2a in 2003 as the most prevalent serotype in Henan Province. The new serotype also became the dominant serotype in 7 of the 10 other provinces under surveillance in China by 2007. The serotype was identified as a variant of serotype X. It differs from serotype X by agglutination to the monovalent anti-IV type antiserum and the group antigen-specific monoclonal antibody MASF IV-I. Genome sequencing of a serotype X variant isolate, 2002017, showed that it acquired a Shigella serotype conversion island, also as an SfX bacteriophage, containing gtr genes for type X-specific glucosylation. Multilocus sequence typing of 15 genes from 37 serotype X variant isolates and 69 isolates of eight other serotypes, 1a, 2a, 2b, 3a, 4a, 5b, X, and Y, found that all belong to a new sequence type (ST), ST91. Pulsed-field gel electrophoresis revealed 154 pulse types with 655 S. flexneri isolates analyzed and identified 57 serotype switching events. The data suggest that S. flexneri epidemics in China have been caused by a single epidemic clone, ST91, with frequent serotype switching to evade infection-induced immunity to serotypes to which the population was exposed previously. The clone has also acquired resistance to multiple antibiotics. These findings underscore the challenges to the current vaccine development and control strategies for shigellosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955273      PMCID: PMC2815595          DOI: 10.1128/JCM.00614-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

Review 1.  Serotype-converting bacteriophages and O-antigen modification in Shigella flexneri.

Authors:  G E Allison; N K Verma
Journal:  Trends Microbiol       Date:  2000-01       Impact factor: 17.079

Review 2.  Pathogenicity islands of Shigella.

Authors:  M Ingersoll; E A Groisman; A Zychlinsky
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

3.  Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri.

Authors:  M M Venkatesan; M B Goldberg; D J Rose; E J Grotbeck; V Burland; F R Blattner
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157.

Authors:  Qi Jin; Zhenghong Yuan; Jianguo Xu; Yu Wang; Yan Shen; Weichuan Lu; Jinhua Wang; Hong Liu; Jian Yang; Fan Yang; Xiaobing Zhang; Jiyu Zhang; Guowei Yang; Hongtao Wu; Di Qu; Jie Dong; Lilian Sun; Ying Xue; Ailan Zhao; Yishan Gao; Junping Zhu; Biao Kan; Keyue Ding; Shuxia Chen; Hongsong Cheng; Zhijian Yao; Bingkun He; Runsheng Chen; Dalong Ma; Boqin Qiang; Yumei Wen; Yunde Hou; Jun Yu
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

5.  Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T.

Authors:  J Wei; M B Goldberg; V Burland; M M Venkatesan; W Deng; G Fournier; G F Mayhew; G Plunkett; D J Rose; A Darling; B Mau; N T Perna; S M Payne; L J Runyen-Janecky; S Zhou; D C Schwartz; F R Blattner
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri.

Authors:  C Buchrieser; P Glaser; C Rusniok; H Nedjari; H D'Hauteville; F Kunst; P Sansonetti; C Parsot
Journal:  Mol Microbiol       Date:  2000-11       Impact factor: 3.501

7.  Nested deletions of the SRL pathogenicity island of Shigella flexneri 2a.

Authors:  S A Turner; S N Luck; H Sakellaris; K Rajakumar; B Adler
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

8.  Type IV O antigen modification genes in the genome of Shigella flexneri NCTC 8296.

Authors:  Mathew M Adams; Gwen E Allison; Naresh K Verma
Journal:  Microbiology       Date:  2001-04       Impact factor: 2.777

9.  Molecular epidemiology of the SRL pathogenicity island.

Authors:  Sally A Turner; Shelley N Luck; Harry Sakellaris; Kumar Rajakumar; Ben Adler
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  A recalibrated molecular clock and independent origins for the cholera pandemic clones.

Authors:  Lu Feng; Peter R Reeves; Ruiting Lan; Yi Ren; Chunxu Gao; Zhemin Zhou; Yan Ren; Jiansong Cheng; Wei Wang; Jianmei Wang; Wubin Qian; Dan Li; Lei Wang
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

View more
  60 in total

1.  Development of a multiplex PCR assay targeting O-antigen modification genes for molecular serotyping of Shigella flexneri.

Authors:  Qiangzheng Sun; Ruiting Lan; Yiting Wang; Ailan Zhao; Shaomin Zhang; Jianping Wang; Yan Wang; Shengli Xia; Dong Jin; Zhigang Cui; Hongqing Zhao; Zhenjun Li; Changyun Ye; Shuxia Zhang; Huaiqi Jing; Jianguo Xu
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

2.  Genomic portrait of the evolution and epidemic spread of a recently emerged multidrug-resistant Shigella flexneri clone in China.

Authors:  Nan Zhang; Ruiting Lan; Qiangzheng Sun; Jianping Wang; Yiting Wang; Jin Zhang; Deshan Yu; Wanfu Hu; Shoukui Hu; Hang Dai; Pengcheng Du; Haiyin Wang; Jianguo Xu
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

3.  In Silico Serotyping Based on Whole-Genome Sequencing Improves the Accuracy of Shigella Identification.

Authors:  Yun Wu; Henry K Lau; Teresa Lee; David K Lau; Justin Payne
Journal:  Appl Environ Microbiol       Date:  2019-03-22       Impact factor: 4.792

Review 4.  The genomic signatures of Shigella evolution, adaptation and geographical spread.

Authors:  Hao Chung The; Duy Pham Thanh; Kathryn E Holt; Nicholas R Thomson; Stephen Baker
Journal:  Nat Rev Microbiol       Date:  2016-02-29       Impact factor: 60.633

Review 5.  Shigella flexneri: an emerging pathogen.

Authors:  Iqbal Nisa; Muhammad Qasim; Nusrat Yasin; Rafi Ullah; Anwar Ali
Journal:  Folia Microbiol (Praha)       Date:  2020-02-05       Impact factor: 2.099

Review 6.  Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas.

Authors:  Margaret Kosek; Pablo Peñataro Yori; Maribel Paredes Olortegui
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

7.  Serotype-converting bacteriophage SfII encodes an acyltransferase protein that mediates 6-O-acetylation of GlcNAc in Shigella flexneri O-antigens, conferring on the host a novel O-antigen epitope.

Authors:  Qiangzheng Sun; Yuriy A Knirel; Jianping Wang; Xia Luo; Sofya N Senchenkova; Ruiting Lan; Alexander S Shashkov; Jianguo Xu
Journal:  J Bacteriol       Date:  2014-08-11       Impact factor: 3.490

8.  Shigella: A Highly Virulent and Elusive Pathogen.

Authors:  Mussaret Bano Zaidi; Teresa Estrada-García
Journal:  Curr Trop Med Rep       Date:  2014-06-01

9.  High prevalence of antibiotic resistance and molecular characterization of integrons among Shigella isolates in Eastern China.

Authors:  Yun Shen; Huimin Qian; Junjun Gong; Feifei Deng; Chen Dong; Lu Zhou; Hongxiong Guo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

10.  Influence of Shigella flexneri 2a O Antigen Acetylation on Its Bacteriophage Sf6 Receptor Activity and Bacterial Interaction with Human Cells.

Authors:  Min Yan Teh; Axel Furevi; Göran Widmalm; Renato Morona
Journal:  J Bacteriol       Date:  2020-11-19       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.